TY - JOUR
T1 - Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer
T2 - acute and early-late toxicity, outcome, and efficacy
AU - Dell’Acqua, Veronica
AU - Surgo, Alessia
AU - Arculeo, Simona
AU - Zerella, Maria Alessia
AU - Bagnardi, Vincenzo
AU - Frassoni, Samuele
AU - Zampino, Maria Giulia
AU - Ravenda, Paola Simona
AU - Rotundo, Maria Saveria
AU - Kraja, Fatjona
AU - Kobiela, Jarek
AU - Spychalski, Piotr
AU - Fodor, Cristiana
AU - Gerardi, Marianna Alessandra
AU - Cattani, Federica
AU - Bazani, Alessia
AU - Petz, Wanda
AU - Glynne-Jones, Robert
AU - Orecchia, Roberto
AU - Leonardi, Maria Cristina
AU - Jereczek-Fossa, Barbara Alicja
N1 - Funding Information:
This study was partially supported by Fondazione IEO-CCM, project title: “AXILL-ART: Biology-based radiotherapy volume definition for 1-2 macrometastatic sentinel lymph nodes without further dissection in breast cancer conservative surgery” and by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds.
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose: To retrospectively review our experience on 84 patients with squamous cell anal canal cancer (SCAC) within 12 months after combined treatment with intensity-modulated RT (IMRT), in terms of acute and early-late toxicity, overall treatment time and interruptions, colostomy-free survival (CFS), and tumor response. Methods: Acute gastrointestinal (GI), genitourinary (GU), and cutaneous (CU) toxicities were assessed according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Early-late toxicity was scored using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring system. Tumor response was evaluated with response evaluation criteria in solid tumors (RECIST) v1.1. Results: Acute toxicity for 84 subjects (100%): severe (≥ G3) GI and skin toxicity was observed in 4 (5%) and 19 patients (23%), respectively. Early-late toxicity for 73 subjects (87%): severe (≥ G3) GI and vulvo-vaginal toxicity was observed in 2 (3%) and 2 (3%) patients, respectively. No acute or early-late severe GU toxicity was reported. A treatment interruption occurred in 65 patients (77%). CFS was 96% (95% CI 89–99) at 6 months and 92% (95% CI 83–96) at 12 months. At 6 months complete response (CR), partial response (PR) and progressive disease (PD) was observed in 70 (83%), 3 (4%), and 7 patients (8%), respectively. At 12 months, CR was observed in 60 patients (81%); eleven patients (15%) experienced PD. Conclusion: Our study showed an excellent clinical result and very low acute toxicity rates, confirming the IMRT as standard of care for curative treatment of anal cancer patients. The current trial was registered with the number IEO N87/11
AB - Purpose: To retrospectively review our experience on 84 patients with squamous cell anal canal cancer (SCAC) within 12 months after combined treatment with intensity-modulated RT (IMRT), in terms of acute and early-late toxicity, overall treatment time and interruptions, colostomy-free survival (CFS), and tumor response. Methods: Acute gastrointestinal (GI), genitourinary (GU), and cutaneous (CU) toxicities were assessed according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Early-late toxicity was scored using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring system. Tumor response was evaluated with response evaluation criteria in solid tumors (RECIST) v1.1. Results: Acute toxicity for 84 subjects (100%): severe (≥ G3) GI and skin toxicity was observed in 4 (5%) and 19 patients (23%), respectively. Early-late toxicity for 73 subjects (87%): severe (≥ G3) GI and vulvo-vaginal toxicity was observed in 2 (3%) and 2 (3%) patients, respectively. No acute or early-late severe GU toxicity was reported. A treatment interruption occurred in 65 patients (77%). CFS was 96% (95% CI 89–99) at 6 months and 92% (95% CI 83–96) at 12 months. At 6 months complete response (CR), partial response (PR) and progressive disease (PD) was observed in 70 (83%), 3 (4%), and 7 patients (8%), respectively. At 12 months, CR was observed in 60 patients (81%); eleven patients (15%) experienced PD. Conclusion: Our study showed an excellent clinical result and very low acute toxicity rates, confirming the IMRT as standard of care for curative treatment of anal cancer patients. The current trial was registered with the number IEO N87/11
KW - Anal cancer
KW - Chemotherapy
KW - Colostomy
KW - IMRT
KW - Radiotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85079435389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079435389&partnerID=8YFLogxK
U2 - 10.1007/s00384-020-03517-x
DO - 10.1007/s00384-020-03517-x
M3 - Article
C2 - 32036405
AN - SCOPUS:85079435389
VL - 35
SP - 685
EP - 694
JO - International Journal of Colorectal Disease
JF - International Journal of Colorectal Disease
SN - 0179-1958
IS - 4
ER -